Pharma Firms Urged To Push For Post-Brexit Regulatory Equivalence Deal
Executive Summary
A mutual recognition agreement between the UK and EU on equivalence of regulatory procedures and processes could provide pharmaceutical companies with some stability and continuity post-Brexit – and save them some money.
You may also be interested in...
Japan Issues Strong Warning Over Brexit
Uncertainty is bad for business and can deter investment, warns Japan in relation to eventual talks on the UK’s exit from the EU. Japan’s preferred Brexit outcome? For the UK to keep both EU law and the European Medicines Agency.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.